. The cell type of these tumors is important for estimating the risk of metastases and the response to chemotherapy. Polyembryoma presents an unusual growth pattern and is sometimes listed as a single histological type, though it might better be regarded as a mixed tumor.[1-3]Intratubular germ cell neoplasia, unclassified.Malignant pure germ cell tumor (showing a single-cell type):Seminoma.Embryonal
Embryoid Bodies and Related Proliferations in Ovarian Germ Cell Tumors. We investigated the frequency and associated pathology of embryoid bodies in ovarian tumors by evaluating neoplasms in which they are known to occur: 100 immature teratomas, 125 malignant mixed germ cell tumors, and 6 polyembryomas. Three immature teratomas contained a single relatively well-formed embryoid body, whereas were present in 25%, invariably associated with foci of immature teratoma (100%) and often with yolk sac tumor (97%), embryonal carcinoma (35%), or both (32%). These foci usually took the form of round to oval aggregates, often well-circumscribed, for which the term "polyembryoma background" has been proposed. The polyembryomas were typically grossly hemorrhagic and occurred in patients from 9 to 43
solid, two polyembryoma/embryoid body and two polyvesicular vitelline) and 81 other GCTT. The percentage of positive cells (0, 1+, 2+, 3+) and the intensity (0, 1, 2, 3) were evaluated regardless of and within each YSTpt pattern. FoxA2 was positive in all YSTpt (24 of 24) and all but one (23 of 24) exhibited 2+/3+ stain, with higher intensity [median value (mv): 2.6] than AFP (1.8) and GPC3 (2.5 ). Both FoxA2 and GPC3 were positive in all microcystic/reticular (24 of 24), myxoid (10 of 10), macrocystic (two of two), endodermal sinus/perivascular (four of four) and polyembryoma/embryoid body (two of two) patterns. Nevertheless, only FoxA2 was positive in all glandular/alveolar (five of five), solid (four of four) and polyvesicular vitelline (two of two) patterns. The intensity of FoxA2
of the ovary account for 2.6% of all ovar-iancancers and mayproduce serumtumor markers that can prove help-ful in the diagnosis and posttreatment surveillance [48]. Alpha-fetoprotein (AFP) can be produced by endodermal sinus (yolk sac) tu-mors, embryonal carcinomas, polyembryomas, and immature terato-mas. Human chorionic gonadotropin (hCG) can be produced bychoriocarcinomas, embryonal carcinomas , polyembryomas, and, inlow levels, in some dysgerminomas and lactate dehydrogenase (LDH)can be a marker for dysgerminoma [48]. Because these tumors tend tooccur in young women and most are unilateral; fertility-sparing surgerywith or without adjuvant therapy can be utilized [48,49]. Although datais limited, recurrences are rare and typically occur within thefirst2 years. Though prognosis for recurrent disease
%), and papillary (11%) were the most common primary patterns (predominant architectural pattern occupying at least 50%), whereas other less common primary patterns included nested (3%), micropapillary (2%), anastomosing glandular (1%), sieve-like glandular (<1%), pseudopapillary (<1%), and blastocyst-like (<1%). Occasionally, EC developed predominantly in the context of polyembryoma-like (6%) and diffuse
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell
and with marijuana use. Beta-hCG is degraded to the beta-core fragment, which is concentrated in urine and is also known as urinary gonadotropin peptide. Urinary gonadotropin fragment and lipid-associated sialic acid are elevated in up to 60% of patients with endometrial cancer.Elevations in beta-hCG are also found in patients with choriocarcinoma of the uterus, embryonal carcinomas, polyembryomas, mixed cell